ANGPTL3 inhibitors achieved a greater reduction in total cholesterol by 49.9% compared to 21.2% for PCSK9 inhibitors in patients with homozygous familial hypercholesterolemia.
Do ANGPTL3 inhibitors improve lipid profiles in patients with homozygous familial hypercholesterolemia compared to PCSK9 inhibitors?
In patients with homozygous familial hypercholesterolemia, ANGPTL3 inhibitors demonstrate superior efficacy in reducing lipid levels compared to PCSK9 inhibitors, particularly in those with negative LDLR genotypes.
Absolute Event Rate: 0% vs 0%
OBJECTIVE: The aim of this meta-analysis was to compare the efficacy of PCSK9 and ANGPTL3 inhibitors in patients with homozygous familial hypercholesterolemia (HoFH). METHODS: We systematically searched selected electronic databases until 30 November 2024. Main end point was the effect of lipid lowering therapy on lipid profile: total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and lipoproteins levels. The secondary end point was adverse clinical effects. RESULTS: A total of 12 trials involving 392 patients with HoFH, were finally included in the meta-analysis. At a median follow-up of 12 months, ANGPTL3 inhibitors achieved greater reductions in TC (- 49.9% versus - 21.2%; p CONCLUSIONS: PCSK9 inhibitors have lower efficacy in reducing lipid levels in HoFH compared with ANGPTL3 inhibitors, with the greatest difference seen in patients with the negative LDLR genotype. Further studies are needed to clarify efficacy across LDLR functional variants.
Bytyçi et al. (Wed,) reported a other. ANGPTL3 inhibitors achieved a greater reduction in total cholesterol by 49.9% compared to 21.2% for PCSK9 inhibitors in patients with homozygous familial hypercholesterolemia.